High--throughput screening of FDA--approved drugs identifies novel immunomodulatory agents for immune-mediated skin diseases

被引：0

作者：

Ghorbanalipoor, S. ^{[1
]}

Matsumoto, K. ^{[1
]}

Heimberg, L. ^{[1
]}

Krause, M. ^{[1
]}

Veldkamp, W. ^{[2
]}

Magens, M. ^{[1
]}

Zanken, J. ^{[1
]}

Vidarsson, G. ^{[3
,4
]}

Visser, R. ^{[3
,4
]}

Kuenzel, S. ^{[5
]}

Recke, A. ^{[6
,7
]}

Samavedam, U. ^{[1
]}

Gupta, Y. ^{[1
]}

Zillikens, D. ^{[6
,7
]}

Bieber, K. ^{[1
]}

Ludwig, R. J. ^{[1
]}

机构：

[1] Univ Lubeck, D-23562 Lubeck, Germany

[2] Radboudumc, Univ Clin, Nijmegen, Netherlands

[3] Sanquin Res, Amsterdam, Netherlands

[4] Landsteiner Lab, Amsterdam, Netherlands

[5] Max Planck Inst Evolutionary Biol, Plon, Germany

[6] Univ Lubeck, Dept Dermatol, D-23562 Lubeck, Germany

[7] Ctr Res Inflammat Skin, D-23562 Lubeck, Germany

来源：

EXPERIMENTAL DERMATOLOGY | 2023年 / 32卷 / 04期

关键词：

D O I：

暂无

中图分类号：

R75 [皮肤病学与性病学];

学科分类号：

100206 ;

摘要：

P094

引用

页码：E46 / E46

页数：1

共 50 条

[21] High-dose intravenous immunoglobulins:: An approach to treat severe immune-mediated and autoimmune diseases of the skin
Rütter, A
Luger, TA
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2001, 44 (06) : 1010 - 1024
[22] PATIENTS' PERSPECTIVE ON CONTINUATION VERSUS TEMPORARY INTERRUPTION OF IMMUNOMODULATORY AGENTS DURING INFECTIONS IN PATIENTS WITH IMMUNE-MEDIATED INFLAMMATORY DISEASES: AN INTERVIEW STUDY
Opdam, M.
Verhoef, L. M.
Vriezekolk, J.
Van den Bemt, B.
Den Broeder, A.
ANNALS OF THE RHEUMATIC DISEASES, 2021, 80 : 1027 - 1028
[23] A high-throughput screen identifies fulvestrant as an enhancer of immune-mediated cytotoxicity of mesenchymal-like lung cancer cells
Hamilton, Duane H.
Mathews-Griner, Lesley
Keller, Jonathan M.
Hu, Xin
Southall, Noel
Marugan, Juan
David, Justin M.
Ferrer, Ferrer
Schlom, Jeffrey
Palena, Claudia
CANCER IMMUNOLOGY RESEARCH, 2017, 5 (03)
[24] HIGH-THROUGHPUT DRUG SCREENING OF FDA-APPROVED CANCER DRUGS REVEALS POTENTIAL THERAPEUTIC APPROACHES FOR ATYPICAL TERATOID RHABDOID TUMOUR
Chong, Wai Chin
Zhukova, Nataliya
Wood, Paul
Downie, Peter A.
Cain, Jason E.
NEURO-ONCOLOGY, 2020, 22 : 280 - 280
[25] Oxidative stress-mediated high-throughput screening identifies novel neuroprotective agents that protect RPE and rescues visual function in models of AMD
Gong, Jie
Cai, Huey
Del Priore, Lucian V.
Fields, Mark Anthony
INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE, 2022, 63 (07)
[26] A High-Throughput Screening Approach To Repurpose FDA-Approved Drugs for Bactericidal Applications against Staphylococcus aureus Small-Colony Variants
Trombetta, Ryan P.
Dunman, Paul M.
Schwarz, Edward M.
Kates, Stephen L.
Awad, Hani A.
MSPHERE, 2018, 3 (05):
[27] High-throughput screening identifies novel agents eliciting hypersensitivity in Fanconi pathway-deficient cancer cells
Gallmeier, Eike
Hucl, Tomas
Brody, Jonathan R.
Dezentje, David A.
Tahir, Khola
Kasparkova, Jana
Brabec, Viktor
Bachman, Kurtis E.
Kern, Scott E.
CANCER RESEARCH, 2007, 67 (05) : 2169 - 2177
[28] Large-Scale Drug Screening in Patient-Derived IDHmut Glioma Stem Cells Identifies Several Efficient Drugs among FDA-Approved Antineoplastic Agents
Trong, Philip Dao
Jungwirth, Gerhard
Yu, Tao
Pusch, Stefan
Unterberg, Andreas
Herold-Mende, Christel
Warta, Rolf
CELLS, 2020, 9 (06)
[29] A high-throughput, flow cytometry-based screening of FDA-approved drugs that induce complement regulator expression on hypoxic human endothelial cells
Pouw, Richard
Sivanesan, Rojini
Senn, Gabriel
Ricklin, Daniel
MOLECULAR IMMUNOLOGY, 2022, 141 : 117 - 118
[30] Screening Compounds with a Novel High-Throughput ABCB1-Mediated Efflux Assay Identifies Drugs with Known Therapeutic Targets at Risk for Multidrug Resistance Interference
Ansbro, Megan R.
Shukla, Suneet
Ambudkar, Suresh V.
Yuspa, Stuart H.
Li, Luowei
PLOS ONE, 2013, 8 (04):

← 1 2 3 4 5 →